MOTS-c Research
MOTS-c Research: What the Mouse Studies Measured
Published by Peptara Labs · Updated · How we research and check our pages
The short answer
MOTS-c research has set no human standard, because no completed human dosing trial has been published. The core evidence is a mouse study by Lee et al. (2015, Cell Metabolism), where MOTS-c activated AMPK and reduced diet-induced obesity and insulin resistance in mice.
This page is general educational information, research-use framing only, not medical advice. Any decision about a research compound belongs with a qualified clinician.
What is MOTS-c, and why is the human picture uncertain?
MOTS-c is a short peptide encoded inside mitochondrial DNA that Lee et al. (2015) showed activates AMPK and improves metabolic measures in mice, but because no human dosing trial has been completed, no established human dose exists.
MOTS-c stands for a 16 amino acid peptide read from the mitochondrial 12S rRNA region. Lee et al. (2015, Cell Metabolism) reported that it works through AMPK, a cellular energy sensor, and that treated mice showed better insulin sensitivity and resistance to diet-induced obesity. Those findings describe an effect in animals, not a demonstrated outcome or a treatment in people. The uncertainty in dosing follows directly from that: the quantitative dose data come from rodents, and rodent doses are set by body weight and route in ways that do not carry over to human use.
How was MOTS-c given in the mouse research?
The most-cited data come from Lee et al. (2015), where mice received MOTS-c by intraperitoneal injection, meaning injection into the abdominal cavity, dosed per kilogram of body weight rather than as a fixed milligram amount for people.
The table below describes how the foundational mouse study set its doses; no human protocol has been established. This is educational, not a prescription or a personal recommendation.
| Model | Route | How the dose was set | Notes | Source |
|---|---|---|---|---|
| Mouse | Intraperitoneal injection | Scaled to each mouse's body weight; varied by experiment | Reported improved insulin sensitivity and reduced diet-induced obesity | Lee et al., 2015, Cell Metabolism |
| Human | Not established | No published human dosing trial | Dose, frequency, and safety thresholds unknown | None published |
Read the table as research context, not as a plan. An amount scaled to the body weight of a small mouse is not a milligram number a person can copy, and the route used in the study is a laboratory route, not a consumer one. The figures exist to describe the experiment, and they only describe animals.
Can a mouse dose be converted to a human dose?
Not reliably: animal-to-human scaling is a rough estimation tool for designing early trials, not a personal dose, and it has never been validated for MOTS-c because no human trial has been completed.
Researchers sometimes estimate a first human amount from animal data using body surface area scaling. That method is built to help design a first human study, and it produces a planning estimate, not a proven dose. For MOTS-c there is no completed human trial to confirm any converted number, so treating a scaled figure as a dose would be guessing. So this page gives no MOTS-c number at all. Every study amount that exists was set for mice in a lab, what we sell is research material meant for the lab bench, and any choice about a person is one to make with a qualified clinician. The honest answer is that the human number is not known.
Is there any human data on MOTS-c?
No completed human dosing trial for MOTS-c has been published, so human dose, frequency, half-life, and safety thresholds are all unestablished, and the evidence rests on animal work such as Lee et al. (2015).
It helps to compare this with peptides that do have a human dosing base. GLP-1 class peptides went through large human dose-finding trials, for example Wilding et al. (2021, New England Journal of Medicine) for semaglutide and Jastreboff et al. (2022, New England Journal of Medicine) for tirzepatide. Those trials tested defined doses in thousands of people and reported outcomes. MOTS-c has nothing of that kind. That gap is not a detail; it is the difference between a compound with a human dosing record and one without. MOTS-c is offered as a research material, and there is no approved human therapeutic use.
How does reconstitution math work for a MOTS-c vial? (reference only)
This is lab-handling arithmetic, not a dose recommendation: after a lyophilized peptide is reconstituted, concentration equals milligrams of peptide divided by milliliters of liquid. Peptara Labs uses 2 mL of bacteriostatic water for every compound, so the concentration depends only on how much powder is in the vial. To run this same arithmetic for any vial without working it out by hand, use the peptide reconstitution calculator.
The table below shows the concentration you get when example vial sizes are mixed with 2 mL. It stops at concentration on purpose. It does not turn any amount into a syringe draw, because MOTS-c has no established human dose to convert.
| Powder in vial | Bacteriostatic water added | Concentration |
|---|---|---|
| 5 mg | 2 mL | 2.5 mg per mL |
| 10 mg | 2 mL | 5 mg per mL |
This is reference arithmetic about concentration only. Each row shows how strong the liquid is after mixing. It is not a dose, not a recommendation, and not injection instructions, and no target amount for a person is shown. What a given individual should do, if anything, is a decision for a qualified clinician.
What safety signals appear in MOTS-c research?
Published MOTS-c safety information is limited to animal studies, so human tolerability, side effects, and long-term safety are not established in the literature.
Lee et al. (2015) reported metabolic changes in mice, such as improved insulin sensitivity and reduced diet-induced obesity, but those are efficacy observations in animals, not a human safety profile. Human pharmacokinetics, including half-life and clearance, are not characterized in published human trials. Absence of reported harm in a mouse study is not evidence of human safety, and the correct summary is that the human safety picture is unknown.
What are the reported benefits of MOTS-c?
The reported benefits are animal findings, not proven human outcomes: in mice, Lee et al. (2015) reported that MOTS-c activated AMPK, improved insulin sensitivity, and increased resistance to diet-induced obesity.
Those three results, AMPK activation, better insulin sensitivity, and resistance to diet-induced obesity, are the effects most often listed as MOTS-c benefits. Read them precisely: they were measured in mice in a single foundational study, they describe a metabolic effect in animals, and they have not been confirmed as benefits in people, because no completed human trial has tested them. The honest framing is that these are promising preclinical observations, not established human benefits.
Is there a MOTS-c dosing protocol?
There is no established human MOTS-c dosing protocol. A protocol would require a completed human trial defining dose, frequency, route, and duration, and none has been published.
What circulates online as a protocol is not drawn from a human study, because the only dose data come from mice in Lee et al. (2015), given by intraperitoneal injection and scaled to body weight. That data describes an experiment in animals; they do not define a schedule for a person. Any protocol for a specific individual is a clinical decision, not something this educational page sets.
Is there a MOTS-c dosage chart?
There is no validated human MOTS-c dosage chart. The only dose data come from the mouse study described in the research table above (Lee et al., 2015), where amounts were set by body weight in an animal experiment, not a human schedule.
A real dosage chart would list human doses by goal or body weight, and that requires completed human dosing trials, which MOTS-c does not have. Charts presented elsewhere as human MOTS-c dosing are not backed by a published human trial. The reference table earlier on this page is the honest version of the data: it describes how the mouse study set its doses and marks the human row as not established.
Related reading
To go deeper, see the main MOTS-c overview and the companion page on MOTS-c side effects. For background on how peptides work as a class, read what are peptides. For the contrast used above between a compound with a human dosing record and one without, see GLP-1 receptor agonists explained.
Keep reading
Related research and verification
MOTS-c Research: FAQ
Is there an established human dose for MOTS-c?
No. No completed human dosing trial has been published, so any human dose is unestablished. The quantitative data come from animal work (Lee et al., 2015).
How was MOTS-c given in the research?
In the foundational mouse study, MOTS-c was given by intraperitoneal injection and scaled to the body weight of each mouse, not as a fixed human amount (Lee et al., 2015).
Does MOTS-c have a known half-life in humans?
Not in the published literature. Human pharmacokinetics, including half-life, have not been characterized in completed human trials; only animal data exist.
How is MOTS-c different from GLP-1 peptides for evidence certainty?
GLP-1 peptides like semaglutide and tirzepatide went through large human dose-finding trials (Wilding et al., 2021; Jastreboff et al., 2022), while MOTS-c has none, so the dosing evidence base is not comparable.
Can I convert a mouse dose to my own dose?
No. Animal-to-human scaling is a rough estimation tool for trial design, not a personal dose, and it has not been validated for MOTS-c.
Who should decide a MOTS-c dose?
A qualified clinician. This page is educational and does not provide dose recommendations.
Is there MOTS-c before and after data in humans?
No. No human before and after data exist for MOTS-c, because no completed human dosing trial has been published. The available results are metabolic measures reported in mice (Lee et al., 2015), not human before and after outcomes.
References
- Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. "The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance." Cell Metabolism 2015;21(3):443-454. PMID 25738459. doi:10.1016/j.cmet.2015.02.009
- Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity" (STEP 1). New England Journal of Medicine 2021;384(11):989-1002. PMID 33567185. doi:10.1056/NEJMoa2032183
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity" (SURMOUNT-1). New England Journal of Medicine 2022;387(3):205-216. PMID 35658024. doi:10.1056/NEJMoa2206038
Sourcing research-grade peptides?
Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.
General educational information only, research-use framing, not medical advice. Confirm the current status where you live and consult a qualified professional before acting.